Also doing business and receiving awards as MBC Research Inc, MBC Pharma is a privately-held pre-clinical stage company engaged in new therapies for metastatic bone disease and bone cancer. The firm has recently demonstratedfirst human proof of concept efficacy in patients with breast or prostate cancer induced bone lesions. MBC Pharmaâs patented technology is built on exploiting bone seeking properties of a well-known class of antiresorptive agents called bisphosphonates, which are used to deliver chemotherapeutic payloads directly to the cancer-induced sites of bone destruction. This is achieved by chemically linking bisphosphonate to chemotherapeutics in such a way that the compound can leave circulation intact and release both drugs (bisphosphonate and chemotherapeutic) in the bone microenvironment. Such anticancer bone-targeting conjugates will localize at the site of tumor cell induced bone destruction, providing a unique combination of antiresorptive and anticancer properties and resulting in increased local concentrations of cytotoxic agents. The aim is to greatly improve efficacy without increasing systemic toxicity of the chemotherapeutic
